Halozyme Therapeutics HALO Preferred Stock Par Value Per Share
Preferred Stock Par Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's preferred stock par value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's preferred stock par value per share?
- Halozyme Therapeutics (HALO) reported preferred stock par value per share of $0.00 in Q1 2026.
- How has Halozyme Therapeutics's preferred stock par value per share changed year-over-year?
- Halozyme Therapeutics's preferred stock par value per share decreased by 0.0% year-over-year, from $0.00 to $0.00.
- What is the long-term trend for Halozyme Therapeutics's preferred stock par value per share?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's preferred stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.00 to $0.00.
- What does preferred stock par value per share mean?
- The par value per share of preferred stock is a nominal value assigned to preferred shares for accounting and legal purposes. It does not reflect the market value or the liquidation preference of the stock. It is primarily a regulatory and historical accounting figure.